Compare SUPN & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SUPN | SLBT |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | 20 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.4B |
| IPO Year | 2010 | N/A |
| Metric | SUPN | SLBT |
|---|---|---|
| Price | $48.15 | $4.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $61.60 | N/A |
| AVG Volume (30 Days) | ★ 916.2K | 236.9K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $392,755,000.00 | N/A |
| Revenue This Year | $22.70 | N/A |
| Revenue Next Year | $19.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $32.21 | $3.23 |
| 52 Week High | $59.68 | $6.25 |
| Indicator | SUPN | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 54.04 | 47.45 |
| Support Level | $47.48 | $3.63 |
| Resistance Level | $52.24 | $4.91 |
| Average True Range (ATR) | 1.58 | 0.74 |
| MACD | 0.10 | -0.03 |
| Stochastic Oscillator | 38.42 | 32.12 |
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.